CSI Market
Sign In | Register

Opus Genetics Inc (IRD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IRD Annual Cash Flow →
Tracking cash flow results across Opus Genetics Inc to Mar 31 2025 helps illustrate how Mar 31 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-65.54
Depreciation & amortization0.01
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.46
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Deferred Research And Development Contribution-
Unrealized Gain On Fair Value Of Put Feature On Common Stock-
Debt Related Commitment Fees And Debt Issuance Costs-
Deferred Lease Expenses-
Impairment Of Intangible Assets Excluding Goodwill-
Non Cash Interest On Convertible Notes Related Party-
Non Cash Discount Amortization On Convertible Notes Related Party-
Gain Loss On Derivative Instruments Net Pretax51.36
Share Settlement With Investors-
Research And Development Expense Including Acquired In Process Cost-
Warrant Financing Costs Reclassified To Financing Activities-
Increase Decrease In Contract Assets And Unbilled Receivables0.19
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.26
Increase (Decrease) in Accounts Payable1.16
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.43
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.14
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.07
Discontinued operations0.00
Net Cash flow from Operating Activities-12.73
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Of Licensing Fees-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.84
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock25.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-45.30
Proceeds From Exercise Of Stock Warrants-
Proceeds From Research Contribution-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents45.09
Proceeds From Issuance Of Common Stock In Connection With Registered Direct Offering-
Proceeds From Issuance Of Common Stock In Connection With At The Market Program-
Payments Of Debt Issuance Costs Shelf Registration-
Payment Of Stock Issuance Costs And Financing-
Proceeds From Issuance Of Common Stock In Connection With At The Market Program And Purchase Agreement-
Share Repurchases For Payment Of Employee Taxes-0.03
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Connection With Private Offering And Private Placement-
Proceeds From Issuance Of Warrants In Connection With Private Offering And Private Placement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities27.60
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.73
Total Cash Flow14.87
4 historic quarters locked

Sign in to unlock the full Opus Genetics Inc cash flow history.

Sign In Create Free Account

About Opus Genetics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 6, 2026
  • Source: ird-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-054381

Figures are derived from filed reports and may be restated. Historical data is subject to revision.